Pregnancy-associated cancers may be linked to an elevated 5-year mortality risk, but the risk varies by tumor site and time of diagnosis, suggests a population-based cohort study.

The 15-year data from the ProtecT trial show low rates of prostate cancer-specific mortality among men with prostate-specific antigen-detected, localized disease regardless of whether they received active monitoring, prostatectomy, or radiotherapy.

Women who undergo hormonal or nonhormonal fertility preservation procedures following breast cancer diagnosis are not at increased risk for relapse or breast cancer-specific mortality, Swedish study findings indicate.

Sex had no significant impact on COVID-19 mortality risk but pooled case fatality rates did vary by cancer type, ranging from 9% with breast cancer to 32% for hematologic cancer, as did the RRs.

All-cause mortality is significantly reduced in men with prostate cancer receiving adjuvant versus early salvage radiotherapy, particularly if they have four or more positive pelvic lymph nodes, research suggests.

TERAVOLT registry investigators have identified seven major risk factors for COVID-19 mortality in patients with thoracic malignancy, with poor ECOG performance status the strongest prognostic marker.

Mortality rates have fallen with time among people with cancer and SARS-CoV-2 infection, show data from the European OnCovid registry.

Initiating biennial breast screening for Black women at age 40 years rather than the US standard of 50 years could substantially reduce Black–White breast cancer mortality disparities without increasing harms, modelling data suggest.

Men who receive platinum-based chemotherapy or radiotherapy for testicular cancer have significantly higher long-term non-testicular cancer mortality rates than the general population, study findings indicate.

Intermittent and lapsed participants had smaller, but still significant, breast cancer mortality risk reductions of 33% and 28%, respectively, relative to nonparticipants.

The health-related quality of life of patients with ductal carcinoma in situ or invasive breast cancer is impaired by their prognosis and treatment, and measuring the extent of impairment could help predict mortality risk, research suggests.

Delaying cancer treatment by even 4 weeks is associated with an increased mortality risk, say researchers who investigated the impact of delays across surgical, systemic therapy, and radiotherapy indications for seven tumor types.

The 542,320 patients with non-hematologic malignancy diagnosed at least 5 years ago did not have an elevated COVID-19 mortality risk.

A pooled analysis has confirmed the high mortality rate among adults with cancer and comorbid COVID-19.

Intensive care admission, ventilation, and mortality rates among people with cancer and SARS-CoV-2 infection do not significantly differ to those among infected people without cancer, US study findings indicate.

Neither specific comorbidities nor tumor or therapy type were significantly associated with increased mortality risk in multivariable analysis.

The 6-month mortality rate in the low-risk cohort was 7%, and the mortality risk was significantly lower than that in the high-risk control group.

Use of positron emission tomography–computed tomography before diagnosis is associated with increased receipt of stage-appropriate treatment and decreased mortality among veterans with non-small-cell lung cancer, research suggests.

Extending mammography screening to include women in their 40s may reduce breast cancer mortality rates compared with a later screening induction without increasing the risk for overdiagnosis, the UK Age trial investigators report.

Turnbull and co-authors suggest: “Prioritisation of patient groups for whom delay would result in most life-years lost warrants consideration as an option for mitigating the aggregate burden of mortality in patients with cancer.”